Aspira Women’s Health, Inc. to Present at MicroCap Rodeo Best Ideas Bowl October 13-16

Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) has been invited to present at the MicroCap Rodeo Best Ideas Bowl, occurring virtually from October 13-16, 2020. The company’s presentation is scheduled for October 14 from 11:30-11:55 am EST, and will be available for live streaming and replay. Aspira focuses on innovative testing solutions for women’s health, specifically addressing ovarian cancer risk assessment and pelvic diseases. Interested parties can register for the webcast or one-on-one meetings via the provided links.

AUSTIN, Texas, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13^th - 16^th, 2020.

Aspira Women’s Health is scheduled to present on Wednesday, October 14 at 11:30-11:55 am EST, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay. Registration to view a webcast of  the presentation can be found at: https://www.webcaster4.com/Webcast/Page/2134/37960

To receive additional information, request an invitation or to schedule a one-on-one meeting, please register at https://microcaprodeo.com/.

About Aspira Women’s Health Inc.
Aspira Women’s Health, Inc. (formerly known as, Vermillion Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.  ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1^® and OVERA^® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.  With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

FAQ

When is Aspira Women’s Health presenting at the MicroCap Rodeo Best Ideas Bowl?

Aspira Women’s Health will present on October 14, 2020, from 11:30-11:55 am EST.

How can I watch Aspira Women’s Health's presentation at the MicroCap Rodeo?

The presentation can be streamed live and is available for replay; registration details are in the press release.

What is Aspira Women’s Health focusing on during the conference?

The company will discuss its innovative testing solutions for women's health, including ovarian cancer risk assessment.

Who can register for one-on-one meetings with Aspira Women’s Health?

Anyone interested in additional information or meetings can register at the MicroCap Rodeo website.

What are some products Aspira Women’s Health offers?

Aspira offers OVA1® plus and ASPIRA GenetiX™ testing options for ovarian malignancy detection and genetic testing.